Fig. 1: Annual distribution of adverse event reports related to male sexual dysfunction received by the FDA Adverse Event Reporting System (FAERS) for each GLP-1 receptor agonists from 2005-2024. | International Journal of Impotence Research

Fig. 1: Annual distribution of adverse event reports related to male sexual dysfunction received by the FDA Adverse Event Reporting System (FAERS) for each GLP-1 receptor agonists from 2005-2024.

From: Male sexual dysfunction associated with GLP-1 receptor agonists: a cross-sectional analysis of FAERS data

Fig. 1

The thin light gray line represents the total number of reports per year. Individual drugs are distinguished by bar styles: dulaglutide (black horizontal stripes), exenatide (diagonal stripes), liraglutide (light gray with horizontal stripes), lixisenatide (solid gray), semaglutide (light gray with black border), and tirzepatide (dark gray with black border).

Back to article page